Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 10/20 | 0.54 |
| ▸ | NOS3 | P29474 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 5/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366773 | 1.00 | NOS2 (0.57) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL28104037 | 1.00 | NOS2 (0.57) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL80890 | 1.00 | NOS2 (0.57) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736042 | 0.81 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL29613341 | 0.81 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736416 | 0.81 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL29794337 | 0.79 | CYP2C19 (0.56) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736266 | 0.78 | NPY1R (0.55) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Tilarginine SCHEMBL23099403 | 0.78 | NOS1 (0.69) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736695 | 0.78 | NOS2 (0.68) | NOS2CYP2C19CYP1A2TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747382-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | Natural Resources Institute (GB) | 2026-05-27 | — | — | EP | claimed |
| US-20250387510-A1 | ADENO-ASSOCIATED VIRUS FORMULATIONS | SPARK THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | claimed |
| EP-4649136-A1 | GENETIC MODIFICATION OF MICROBES FOR PRODUCTION OF NITROGEN AND CARBON-CONTAINING COMPOUNDS | Fertis India Pvt Ltd (IN) | 2025-11-19 | — | — | EP | claimed |
| EP-4638765-A2 | ADENO-ASSOCIATED VIRUS FORMULATIONS | Spark Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| US-12404526-B2 | Enhancing agents for improved cell transfection and/or rAAV vector production | SPARK THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | claimed |
| US-20250194603-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | NAT RESOURCES INSTITUTE (GB) | 2025-06-19 | — | — | US | claimed |
| WO-2025128977-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | NATIONAL RESOURCES INSTITUTE (GB) | 2025-06-19 | — | — | WO | claimed |
| US-20250179525-A1 | METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-06-05 | — | — | US | claimed |
| EP-3983127-B1 | PLASMA SEPARATION AND SAMPLE METERING DEVICE AND METHODS OF USE RELATED THERETO | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2025-04-23 | — | — | EP | claimed |
| WO-2025019548-A9 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | NATIONAL RESOURCES INSTITUTE (GB) | 2025-04-17 | — | — | WO | claimed |
| EP-4192515-A2 | VESICLE TARGETING PROTEINS AND USES OF SAME | Amicus Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | claimed |
| US-20230048658-A1 | DIRECT SELECTION OF CELLS EXPRESSING HIGH LEVELS OF HETEROMERIC PROTEINS USING GLUTAMINE SYNTHETASE INTRAGENIC COMPLEMENTATION VECTORS | AMGEN INC. (US) | 2023-02-16 | — | — | US | claimed |
| CN-115298270-A | Method for preparing thermochromic water-based gel ink composition and thermochromic water-based gel ink composition thereof | 法国比克公司 | 2022-11-04 | — | — | CN | claimed |
| WO-2022183210-A1 | TISSUE-SPECIFIC METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114965801-A | Application of metabolic marker in preparation of oral cancer diagnosis kit | 上海交通大学医学院附属第九人民医院 | 2022-08-30 | — | — | CN | claimed |
| US-20220266241-A1 | PLASMA SEPARATION AND SAMPLE METERING DEVICE AND KITS AND METHODS OF USE RELATED THERETO | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2022-08-25 | — | — | US | claimed |
| EP-3983127-A1 | PLASMA SEPARATION AND SAMPLE METERING DEVICE AND KITS AND METHODS OF USE RELATED THERETO | Siemens Healthcare Diagnostics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| CN-110346466-B | Construction method for enhancing model of seleno-aminopolysaccharide on immune mechanism of black porgy based on liver metabonomics research | 舟山出入境检验检疫局综合技术服务中心 | 2022-04-08 | — | — | CN | claimed |
| CN-114236025-A | Liquid phase mass spectrum method for simultaneously determining 43 amino acids without using ion pair reagent and non-derivatization | 浙江博圣生物技术股份有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114047263-A | Application of metabolic marker in preparation of detection reagent or detection object for diagnosing AIS (automatic identification system) and kit | 复旦大学附属中山医院厦门医院 | 2022-02-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387510-A1 | ADENO-ASSOCIATED VIRUS FORMULATIONS | CACNA1D, CACNA1S, SCN1A | NOS2 4077/4885CYP2C19 3861/4885CYP1A2 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.